What's in Hikma Pharmaceuticals's pipeline?

Hikma Pharmaceuticals has 8 drugs in our index: 8 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Hikma Pharmaceuticals's portfolio?

Top competitors by shared drug class: , Adapt, Averitas, Bdsi, Caraco.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hikma.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Hikma Pharmaceuticals — Portfolio Competitive Intelligence Brief

Hikma Pharmaceuticals (HIK.L) pipeline: 8 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

HIK.L (LSE) 8 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Revex	NALMEFENE	marketed	Opioid Antagonist	Kappa-type opioid receptor	Neuroscience	1995-01-01
Lithium Citrate	LITHIUM CITRATE	marketed	lithium	Glycogen synthase kinase-3	Metabolic	1980-01-01
Reglan	METOCLOPRAMIDE	marketed	Dopamine-2 Receptor Antagonist	D(3) dopamine receptor	Metabolic	1979-01-01
Reglan	Metoclopramide Hydrochloride	marketed	Prokinetic agent	Acetylcholine receptor sensitization; dopamine antagonism (implied)	Metabolic	1979-01-01
Dopram	DOXAPRAM	marketed	Respiratory Stimulant	Cytochrome P450 2D6	Neuroscience	1965-01-01
Hydrocortisone And Acetic Acid	ACETIC ACID	marketed	acetic acid	Tyrosine-protein kinase Lck	Immunology	1960-01-01
Robaxin	METHOCARBAMOL	marketed	Muscle Relaxant [EPC]	Carbonic anhydrase 1	Pain	1957-01-01
Norgesic	caffeine	marketed	Central Nervous System Stimulant [EPC]	Adenosine receptor A2a	Metabolic	1948-01-01

Therapeutic area mix

Metabolic · 4
Neuroscience · 2
Immunology · 1
Pain · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2029-12-22 — Reglan · 11628150 · Formulation · US
2029-12-22 — Reglan · 11020361 · Method of Use · US
2029-12-22 — Reglan · 12194009 · Method of Use · US
2029-12-22 — Reglan · 12194008 · Method of Use · US
2029-12-22 — Reglan · 11813231 · Formulation · US
2030-05-16 — Reglan · 8334281 · Formulation · US
2038-11-17 — Reglan · 12377064 · Method of Use · US
2044-10-09 — Robaxin · 12390439 · Formulation · US

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Adapt · 1 shared drug class
Averitas · 1 shared drug class
Bdsi · 1 shared drug class
Caraco · 1 shared drug class
Cubist Pharms · 1 shared drug class
Dong-A ST Co., Ltd. · 1 shared drug class
Impax Labs · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hikma Pharmaceuticals:

Cite this brief

Drug Landscape (2026). Hikma Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hikma. Accessed 2026-05-13.